Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» FDA Grants Fast Track Designation to Bayer's Investigational Compound Radium-223 Chloride for the Treatment of Castration-Resistant Prostate Cancer That Has Spread to the Bone
FDA Grants Fast Track Designation to Bayer's Investigational Compound Radium-223 Chloride for the Treatment of Castration-Resistant Prostate Cancer That Has Spread to the Bone
FDA Grants Fast Track Designation to Bayer's Investigational Compound Radium-223 Chloride for the Treatment of Castration-Resistant Prostate Cancer That Has Spread to the Bone
Submitted by
admin
on August 23, 2011 - 10:53am
Source:
Marketwatch
News Tags:
FDA
fast track
Bayer
prostate cancer
radium-223 chloride
Headline:
FDA Grants Fast Track Designation to Bayer's Investigational Compound Radium-223 Chloride for the Treatment of Castration-Resistant Prostate Cancer That Has Spread to the Bone
Do Not Allow Advertisers to Use My Personal information
